Anti-Epileptics (Migraine) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 44 Pages
|抗癲癇藥(用作偏頭痛治療藥):市場預測與分析 Anti-Epileptics (Migraine) - Forecast and Market Analysis to 2023|
|出版日期: 2014年03月31日||內容資訊: 英文 44 Pages||
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
Anti-epileptics were originally developed as treatments for epileptic seizures; however, due to the well-conducted placebo-controlled trials for migraine, they have demonstrated efficacy in the prophylaxis of migraine, with Depakene (valproic acid) and Topamax (topiramate) securing FDA approval for the prophylactic treatment of migraines.